Market capitalization | $254.40m |
Enterprise Value | $204.88m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.87 |
P/S ratio (TTM) P/S ratio | 6.04 |
P/B ratio (TTM) P/B ratio | 3.84 |
Sales growth (TTM) Sales growth | 59.59% |
Turnover (TTM) Turnover | $42.09m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
6 Analysts have issued a CVRx Inc forecast:
6 Analysts have issued a CVRx Inc forecast:
Dec '23 | |
Current assets | 112 112 |
Fixed assets | 3.14 3.14 |
Total assets | 115 115 |
Dec '23 | |
Equity | 76 76 |
Debt capital | 39 39 |
Total capital | 115 115 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.
Head office | United States |
CEO | Kevin Hykes |
Employees | 200 |
Founded | 2001 |
Website | www.cvrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.